Chemoinformaics analysis of (E)-3-Hydroxyfarnesa-1,6,10-trien-9-yl isobutyrate
Molecular Weight | 308.462 | nRot | 9 |
Heavy Atom Molecular Weight | 276.206 | nRig | 4 |
Exact Molecular Weight | 308.235 | nRing | 0 |
Solubility: LogS | -3.932 | nHRing | 0 |
Solubility: LogP | 4.16 | No. of Aliphatic Rings | 0 |
Acid Count | 0 | No. of Aromatic Rings | 0 |
Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
Atoms Count | 54 | No. of Aliphatic Hetero Cycles | 0 |
No. of Heavy Atom | 22 | No. of Aromatic Carbocycles | 0 |
nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
nBridge Head | 0 | No. Saturated Carbocycles | 0 |
No. of Hydrogen atom | 32 | No. of Saturated Hetero Cycles | 0 |
No. of Carbon atom | 19 | No. of Saturated Rings | 0 |
No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
nHA | 3 | APOL | 55.4734 |
nHD | 1 | BPOL | 34.7066 |
QED | 0.501 |
Synth | 4.07 |
Natural Product Likeliness | 2.724 |
NR-PPAR-gamma | 0.029 |
Lipinski | Accepted |
Pfizer | Rejected |
GSK | Rejected |
Golden Triangle | Accepted |
Pgp-inh | 0.932 |
Pgp-sub | 0.005 |
HIA | 0.012 |
CACO-2 | -4.484 |
MDCK | 0.0000242 |
BBB | 0.791 |
PPB | 0.939693 |
VDSS | 1.554 |
FU | 0.0972184 |
CYP1A2-inh | 0.067 |
CYP1A2-sub | 0.161 |
CYP2c19-inh | 0.565 |
CYP2c19-sub | 0.86 |
CYP2c9-inh | 0.25 |
CYP2c9-sub | 0.716 |
CYP2d6-inh | 0.054 |
CYP2d6-sub | 0.086 |
CYP3a4-inh | 0.826 |
CYP3a4-sub | 0.437 |
CL | 7.163 |
T12 | 0.216 |
hERG | 0.005 |
Ames | 0.017 |
ROA | 0.007 |
SkinSen | 0.465 |
Carcinogencity | 0.099 |
EI | 0.068 |
Respiratory | 0.017 |
NR-Aromatase | 0.013 |
Antiviral | Yes |
Prediction | 0.568534 |